President Biden recently set a goal of slashing cancer death rates by at least 50 percent in the next 25 years — and announced billions of dollars in new research funding to make it a reality. It’s a plan with sky-high ambitions, a real “cancer moonshot,” as the president has branded it.
In their quest to lower drug prices, some US leaders have identified a convenient scapegoat: patents.
On the question of taking action to lower prescription drug prices, progressive lawmakers are of two minds. Some argue that Congress should simply pass legislation to allow the government to set the price for prescription medications. That approach, whether wise on policy grounds or not, at least has the virtue of fidelity to our constitutional
Walter G. Copan Opinion: Removing patent rights to lower drug costs is dangerous precedent The Denver Post
Paul R. Michel U.S. patent system weakens: Protect IP to keep American tech at the top VentureBeat
Paul R. Michel https://www.washingtontimes.com/news/2022/mar/16/chinas-formidable-technology-challenge/ The International Business Times
Adam Mossoff The U.S. must fix its innovation engine: the patent system STAT
Paul R. Michel https://www.ibtimes.com/us-economy-2022-diversity-inclusion-heartland-3425396 The International Business Times
Andrei Iancu, David Kappos, and Paul R. Michel https://fortune.com/2022/03/04/new-covid-pills-patents-pfizer-merk-ip-pandemic-pharma-health-iancu-kappos-michel/ Fortune
Paul R. Michel https://news.trust.org/item/20220218102516-a1p08 Reuters
Adam Mossoff Thank You, Senator Tillis, for Recognizing the Need for Evidence-Based Policymaking in Patent Law IPWatchdog
